The Indian road is bumpy As with peers of similar size, Sun Pharma's strongest domain is the home market, netting 26% of its overall revenue.
Read more: Sales at home are sluggish. US rivals are pinning it down. Can Dilip Shanghvi revive Sun Pharma?